Form 4: Beta Bionics CCO Mark Hopman Reports Equity Transactions

Beta Bionics Chief Commercial Officer Mark Hopman reported the acquisition of restricted stock units and stock options, alongside a sale of shares to cover tax obligations.

Summary

• Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc. (BBNX), acquired 109,105 shares of Common Stock as a restricted stock unit (RSU) award on February 27, 2026, at a price of $0.
• Hopman also acquired 58,749 employee stock options on February 27, 2026, with an exercise price of $12.63 and an expiration date of February 26, 2036. These options will vest in 36 equal monthly installments starting March 1, 2026.
• On March 2, 2026, Hopman sold 834 shares of Common Stock at a weighted average price of $12.3616 per share to cover tax withholding obligations related to the vesting of restricted stock units.
• Following these transactions, Hopman beneficially owns 139,486 shares of Common Stock and 58,749 employee stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, reflecting standard executive compensation practices and insider ownership, with no significant red flags or extraordinary positive news.

Positives

• Acquisition of 109,105 restricted stock units (RSUs) at a price of $0, indicating a grant of equity compensation.
• Grant of 58,749 employee stock options with an exercise price of $12.63, aligning management incentives with shareholder value.

Negatives

• Sale of 834 shares of Common Stock at a weighted average price of $12.3616 to cover tax withholding obligations, which is a common practice but reduces direct share ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that equity grants to Chief Commercial Officers are standard practice in the biotechnology and medical device sectors, aligning executive incentives with long-term company performance and shareholder value. The sale of shares for tax withholding is also a routine event for executives receiving equity compensation.

Stakeholder Impact

• Shareholders: Increased alignment of executive interests with shareholder value through equity grants. Minor dilution from RSU vesting is typical.
• Employees: Reflects the company's ongoing equity compensation strategy for key personnel.

Next Steps

• Continued vesting of 58,749 employee stock options in 36 equal monthly installments starting March 1, 2026.

Key Dates

Recommendation

This Form 4 filing details routine executive compensation activities, including equity grants and a tax-related share sale. It does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The transactions are standard for an executive receiving equity compensation, suggesting no immediate positive or negative catalysts for the stock price based solely on this filing.

Keywords

Beta Bionics, BBNX, Mark Hopman, Chief Commercial Officer, SEC Form 4, Insider Trading, Restricted Stock Units, Stock Options, Equity Incentive Plan, Tax Withholding